SLC5A2 and chronic kidney disease: In addition, their confidence was high in their knowledge of the next steps for appropriate treatment, and they felt adept at selecting proper treatment and management to prevent the progression of CKD, including the beneficial effect of SGLT2-Is and glucagon-like peptide 1 receptor agonists.